Page last updated: 2024-08-24

triazoles and ly 518674

triazoles has been researched along with ly 518674 in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (70.00)29.6817
2010's3 (30.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barr, RJ; Bean, JS; Bensch, WR; Dominianni, SJ; Huang, N; Kauffman, RF; Luffer-Atlas, D; Maise, DE; Mantlo, NB; Mayhugh, D; Montrose-Rafizadeh, C; Osborne, J; Rungta, D; Saeed, A; Singh, J; Thompson, RC; Wang, X; Xu, Y; Yumibe, NP; Zink, RW1
Bean, J; Bensch, W; Kauffman, R; Mantlo, N; McClelland, P; Montrose, C; Singh, JP; Wagle, A; Wang, G1
Gomez, EV; Howey, DC; McErlean, E; Nicholls, SJ; Nissen, SE; Russo, JM; Wang, MD; Wolski, K1
Gonzalez, FJ; Hossain, MA; Tsujita, M; Yokoyama, S1
Bloedon, LT; Duffy, D; Dunbar, RL; Fuki, IV; Gadi, R; Harris, CJ; Howey, DC; McCoy, M; Millar, JS; Movva, R; Rader, DJ; Shah, A; Wang, MD; Wolfe, ML1
Akita, N; Fukutomi, T; Gonzalez, FJ; Hossain, MA; Kimura, G; Ogata, M; Staels, B; Suzuki, S; Tsujita, M; Yokoyama, S1
Kim, JB; Mahdavi, H; Navab, M; Safarpour, S; Tien, DA1
Millar, JS; Rader, DJ; Shah, A1
Baccei, CS; Bravo, Y; Broadhead, A; Bundey, R; Chen, A; Clark, R; Correa, L; Jacintho, JD; Lorrain, DS; Messmer, D; Prasit, P; Stebbins, K; Stock, N1
Khera, AV; Millar, JS; Rader, DJ; Ruotolo, G; Wang, MD1

Reviews

1 review(s) available for triazoles and ly 518674

ArticleYear
The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans.
    Atherosclerosis, 2010, Volume: 210, Issue:1

    Topics: Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Humans; PPAR alpha; Propionates; Triazoles

2010

Trials

3 trial(s) available for triazoles and ly 518674

ArticleYear
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
    JAMA, 2007, Mar-28, Volume: 297, Issue:12

    Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; PPAR alpha; Propionates; Pyrroles; Triazoles

2007
Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Deuterium; Double-Blind Method; Female; Humans; Kinetics; Male; Metabolic Syndrome; Middle Aged; Placebos; PPAR alpha; Propionates; Triazoles; Triglycerides; Young Adult

2009
Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome.
    European heart journal, 2015, Nov-14, Volume: 36, Issue:43

    Topics: Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Female; Humans; Male; Metabolic Syndrome; Middle Aged; PPAR alpha; Propionates; Triazoles

2015

Other Studies

6 other study(ies) available for triazoles and ly 518674

ArticleYear
Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.
    Journal of medicinal chemistry, 2003, Nov-20, Volume: 46, Issue:24

    Topics: Administration, Oral; Animals; Apolipoprotein A-I; Binding, Competitive; Biological Availability; Cell Line; Dogs; Drug Design; Humans; Mice; Mice, Transgenic; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Transcription Factors; Transfection; Triazoles

2003
Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipi
    Molecular pharmacology, 2005, Volume: 68, Issue:3

    Topics: Animals; Apolipoprotein A-I; Base Sequence; Cells, Cultured; Cholesterol, HDL; DNA Primers; Humans; In Vitro Techniques; Liver; Macaca fascicularis; Mice; Mice, Transgenic; PPAR alpha; Propionates; RNA, Messenger; Triazoles

2005
Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.
    Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Blotting, Western; Cells, Cultured; Fenofibrate; Gemfibrozil; Gene Expression Regulation; Hepatocytes; Hypolipidemic Agents; Lipoproteins, HDL; Mice; Mice, Inbred C57BL; Mice, Knockout; Peroxisome Proliferator-Activated Receptors; Propionates; Triazoles

2008
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
    Atherosclerosis, 2009, Volume: 205, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Cell Line, Tumor; Fenofibrate; Fibroblasts; Gemfibrozil; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pioglitazone; PPAR delta; PPAR gamma; Propionates; Thiazoles; Thiazolidinediones; Triazoles

2009
Dyslipidemia and cardiovascular diseases.
    Current opinion in lipidology, 2009, Volume: 20, Issue:2

    Topics: Benzimidazoles; Cardiovascular Diseases; Dyslipidemias; Humans; Lipoproteins, HDL; Niacin; Propionates; Triazoles

2009
Identification of the first potent, selective and bioavailable PPARα antagonist.
    Bioorganic & medicinal chemistry letters, 2014, May-15, Volume: 24, Issue:10

    Topics: Animals; Butyrates; Humans; Mice; Molecular Structure; Oxazoles; Phenylurea Compounds; PPAR alpha; Propionates; Structure-Activity Relationship; Sulfonamides; Triazoles; Tyrosine

2014